Compare Novo Nordisk A/S (NVO) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ralph Lauren Corp — how do they compare? Novo Nordisk A/S trades at $46.15 (market cap $207.31B), while Ralph Lauren Corp trades at $397.75 (market cap $24.24B). The key difference: Novo Nordisk A/S is far larger — about 8.6× Ralph Lauren Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| NVO | RL | |
|---|---|---|
Market Cap | $207.31B | $24.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $414.25 |
52-Week Low | $35.29 | $285.35 |
Enterprise Value | $222.02B | $25.31B |
Dividend Yield | 3.76% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.
The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
